FY2025 EPS Estimates for Indivior Reduced by Northland Capmk

Indivior PLC (NASDAQ:INDV) – Research analysts at Northland Capmk cut their FY2025 earnings estimates for Indivior in a research report issued to clients and investors on Thursday, February 20th. Northland Capmk analyst C. Byrnes now anticipates that the company will earn $0.90 per share for the year, down from their previous estimate of $1.00. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, February 20th. The company reported $0.32 EPS for the quarter, hitting the consensus estimate of $0.32. The business had revenue of $298.00 million during the quarter, compared to analyst estimates of $262.35 million. Indivior had a negative net margin of 3.96% and a negative return on equity of 241.73%.

A number of other brokerages have also issued reports on INDV. RODMAN&RENSHAW upgraded shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw started coverage on shares of Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price for the company.

Indivior Stock Performance

Indivior stock opened at $8.47 on Monday. The company has a 50-day simple moving average of $11.45 and a 200-day simple moving average of $10.81. The firm has a market capitalization of $1.17 billion, a P/E ratio of -24.19 and a beta of 0.73. Indivior has a one year low of $7.33 and a one year high of $23.22.

Hedge Funds Weigh In On Indivior

A number of institutional investors and hedge funds have recently bought and sold shares of INDV. GF Fund Management CO. LTD. bought a new position in shares of Indivior during the 4th quarter valued at about $36,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Indivior during the 4th quarter valued at about $56,000. Lazard Asset Management LLC bought a new position in shares of Indivior during the 4th quarter valued at about $57,000. Stifel Financial Corp bought a new position in shares of Indivior during the 3rd quarter valued at about $100,000. Finally, Melqart Asset Management UK Ltd bought a new position in shares of Indivior during the 3rd quarter valued at about $132,000. Institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.